Tag - YMAB

Janney Montgomery Scott initiated coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and fair value estimate of $45. The stock closed at $35.03 on April 30. Y-mAbs is developing immunotherapies for...